CHDI Foundation ( CHDI Foundation)

Primary tabs

CHDI Foundation's picture

Management

Contact Address

About CHDI Foundation

CHDI Foundation is a privately-funded, not-for-profit biomedical research organization devoted to a single disease – Huntington’s disease. Our mission is to develop drugs that will slow the progression of Huntington’s disease and provide meaningful clinical benefit to patients as quickly as possible. To achieve this CHDI manages a diverse portfolio of research projects through a novel virtual model that encourages scientific collaboration to more directly connect academic research, drug discovery and clinical development. This helps bridge the translational gap that often exists between academic and industrial research pursuits, and which adds costly delays to therapeutic development. Our activities extend from exploratory biology to the identification and validation of therapeutic targets, and from drug discovery and development to clinical studies and trials.

CHDI Foundation press release, blog etc

Thu, 06/20/2019 - 16:41 Huntingtons Disease Society of America and CHDI Foundation launch HD Legacy to promote brain donation for HD research
Tue, 04/09/2019 - 09:59 Charles River Laboratories and CHDI Foundation Extend Huntingtons Disease Collaboration
Wed, 12/19/2018 - 11:04 New Enroll-HD clinical dataset now available
Thu, 11/15/2018 - 23:48 CHDI Foundation extends collaboration with IRBM to accelerate development of Huntingtons disease therapeutics
Thu, 11/01/2018 - 18:32 C-Path, CHDI and CDISC announce Therapeutic Area User Guide for Huntingtons disease
Thu, 08/30/2018 - 14:12 Evotec and CHDI Foundation extend ongoing collaboration to fight Huntingtons disease
Wed, 04/04/2018 - 09:07 PTC Therapeutics and CHDI Foundation Announce a Collaboration on a Small-Molecule Therapeutic for Huntingtons Disease
Wed, 03/28/2018 - 13:15 C-Path and CHDI launch consortium to accelerate development of Huntingtons disease therapies
Mon, 12/11/2017 - 10:50 Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntingtons Disease
Thu, 11/16/2017 - 12:09 13th Annual HD Therapeutics Conference
Mon, 09/11/2017 - 11:39 C-Path, CHDI Foundation, and CDISC Announce Public Review Period for Huntingtons Disease Therapeutic Area User Guide
Wed, 08/30/2017 - 10:47 HudsonAlpha and CHDI Foundation announce Huntington disease collaboration
Wed, 06/21/2017 - 20:46 Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntingtons Disease Completed and Open-Label Extension Study to Open in 2H 2017
Thu, 06/01/2017 - 11:37 Voyager Therapeutics Selects Lead Clinical Candidate for Huntingtons Disease
Thu, 05/11/2017 - 14:35 12th Annual HD Therapeutics Conference
Mon, 10/31/2016 - 09:32 Critical Path Institute and CHDI Foundation, Inc. establish a consortium to expedite approval of Huntingtons disease therapeutics
Mon, 09/12/2016 - 13:27 Voyager Therapeutics and CHDI Foundation Collaborate to Develop Novel Gene Therapy for Huntingtons Disease
Tue, 07/21/2015 - 19:42 Isis Pharmaceuticals initiates clinical study of ISIS-HTT Rx in patients with Huntington’s disease